Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma.

Seystahl K, Hentschel B, Loew S, Gramatzki D, Felsberg J, Herrlinger U, Westphal M, Schackert G, Thon N, Tatagiba M, Pietsch T, Reifenberger G, Löffler M, Wick W, Weller M; German Glioma Network.

J Cancer Res Clin Oncol. 2019 Nov 21. doi: 10.1007/s00432-019-03086-9. [Epub ahead of print]

PMID:
31754832
2.

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.

Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R.

Clin Cancer Res. 2004 Mar 15;10(6):1871-4.

3.

Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.

Schraml P, von Teichman A, Mihic-Probst D, Simcock M, Ochsenbein A, Dummer R, Michielin O, Seifert B, Schläppi M, Moch H, von Moos R.

Oncol Rep. 2012 Aug;28(2):654-8. doi: 10.3892/or.2012.1826. Epub 2012 May 18.

PMID:
22614944
4.

Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.

Morandi L, Franceschi E, de Biase D, Marucci G, Tosoni A, Ermani M, Pession A, Tallini G, Brandes A.

BMC Cancer. 2010 Feb 18;10:48. doi: 10.1186/1471-2407-10-48.

5.

Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.

Reifenberger G, Hentschel B, Felsberg J, Schackert G, Simon M, Schnell O, Westphal M, Wick W, Pietsch T, Loeffler M, Weller M; German Glioma Network.

Int J Cancer. 2012 Sep 15;131(6):1342-50. doi: 10.1002/ijc.27385. Epub 2012 Jan 11.

6.

CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.

Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L, García-Lopez JL, Piquer J, Safont MJ, Balaña C, Sanchez-Cespedes M, García-Villanueva M, Arribas L, Esteller M.

Clin Cancer Res. 2004 Aug 1;10(15):4933-8.

7.

O6-methylguanine-DNA methyltransferase activity is associated with response to alkylating agent therapy and with MGMT promoter methylation in glioblastoma and anaplastic glioma.

Bobola MS, Alnoor M, Chen JY, Kolstoe DD, Silbergeld DL, Rostomily RC, Blank A, Chamberlain MC, Silber JR.

BBA Clin. 2015 Jun 1;3:1-10.

8.

MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.

Gutenberg A, Bock HC, Brück W, Doerner L, Mehdorn HM, Roggendorf W, Westphal M, Felsberg J, Reifenberger G, Giese A.

Br J Neurosurg. 2013 Dec;27(6):772-8. doi: 10.3109/02688697.2013.791664. Epub 2013 May 11.

PMID:
23662801
9.

Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?

Pala A, Schmitz AL, Knoll A, Schneider M, Hlavac M, König R, Wirtz CR, Coburger J.

Clin Neurol Neurosurg. 2018 Apr;167:6-10. doi: 10.1016/j.clineuro.2018.02.003. Epub 2018 Feb 5.

PMID:
29425743
10.

O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.

Lechapt-Zalcman E, Levallet G, Dugué AE, Vital A, Diebold MD, Menei P, Colin P, Peruzzy P, Emery E, Bernaudin M, Chapon F, Guillamo JS.

Cancer. 2012 Sep 15;118(18):4545-54. doi: 10.1002/cncr.27441. Epub 2012 Feb 22.

11.

Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.

Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, Schackert G, Kreth FW, Pietsch T, Löffler M, Weller M, Reifenberger G, Tonn JC; German Glioma Network.

Int J Cancer. 2011 Aug 1;129(3):659-70. doi: 10.1002/ijc.26083.

12.

MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.

Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W; DIRECTOR Study Group.

Clin Cancer Res. 2015 May 1;21(9):2057-64. doi: 10.1158/1078-0432.CCR-14-2737. Epub 2015 Feb 5.

13.

Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.

Iaccarino C, Orlandi E, Ruggeri F, Nicoli D, Torricelli F, Maggi M, Cerasti D, Pisanello A, Pedrazzi G, Froio E, Crafa P, D'Abbiero N, Michiara M, Ghadirpour R, Servadei F.

Clin Neurol Neurosurg. 2015 May;132:1-8. doi: 10.1016/j.clineuro.2015.01.029. Epub 2015 Feb 7.

PMID:
25723791
14.

O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.

Kreth S, Thon N, Eigenbrod S, Lutz J, Ledderose C, Egensperger R, Tonn JC, Kretzschmar HA, Hinske LC, Kreth FW.

PLoS One. 2011 Feb 18;6(2):e17156. doi: 10.1371/journal.pone.0017156.

15.

Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.

Metellus P, Coulibaly B, Nanni I, Fina F, Eudes N, Giorgi R, Barrie M, Chinot O, Fuentes S, Dufour H, Ouafik L, Figarella-Branger D.

Cancer. 2009 Oct 15;115(20):4783-94. doi: 10.1002/cncr.24546.

16.

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R.

N Engl J Med. 2005 Mar 10;352(10):997-1003.

17.

Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation.

McDonald KL, Tabone T, Nowak AK, Erber WN.

Oncol Lett. 2015 May;9(5):2063-2067. Epub 2015 Feb 20.

18.

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.

Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, Aldape KD.

Neuro Oncol. 2010 Feb;12(2):116-21. doi: 10.1093/neuonc/nop020. Epub 2009 Dec 14. Erratum in: Neuro Oncol. 2010 Jun;12(6):617.

19.

MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.

Sadones J, Michotte A, Veld P, Chaskis C, Sciot R, Menten J, Joossens EJ, Strauven T, D'Hondt LA, Sartenaer D, Califice SF, Bierau K, Svensson C, De Grève J, Neyns B.

Eur J Cancer. 2009 Jan;45(1):146-53. doi: 10.1016/j.ejca.2008.09.002. Epub 2008 Oct 20.

PMID:
18945611
20.

MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.

Switzeny OJ, Christmann M, Renovanz M, Giese A, Sommer C, Kaina B.

Clin Epigenetics. 2016 May 5;8:49. doi: 10.1186/s13148-016-0204-7. eCollection 2016.

Supplemental Content

Support Center